<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Meropenam Dosage Information</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            padding: 20px;
            background-color: #f9f9f9;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background-color: #fff;
            border-radius: 10px;
            box-shadow: 0px 4px 8px rgba(0, 0, 0, 0.1);
        }

        h1 {
            color: #fcf2f2;
            font-size: 28px;
            font-weight: bold;
            padding: 10px;
            border: 2px solid #afaaaa;
            border-radius: 10px;
            background-color: #2c8ed0;
            text-align: center; /* Center the text */
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 16px;
            text-align: center;
        }

        th, td {
            padding: 12px;
            border-bottom: 1px solid #ddd;
        }

        th {
            background-color: #f2f2f2;
        }

        .highlight {
            background-color: #c3e6cb;
        }

        .dose-range {
            color: red;
            font-weight: bold;
        }

        .section-title {
            margin-top: 20px;
            font-size: 18px;
            font-weight: bold;
        }

        .section-header {
        background-color: #f2f2f2; /* สีเทาอ่อน */
        font-weight: bold;
        padding: 10px;
        text-align: left; /* ชิดซ้าย */
        border-radius: 5px; /* เพิ่มขอบมน */
        margin-bottom: 10px; /* เพิ่มช่องว่างด้านล่าง */
        }

        .highlight-dose {
        color: #ff5733; /* สีแดง */
        font-weight: bold; /* ข้อความตัวหนา */
        background-color: #fbe9e7; /* สีพื้นหลังแดงอ่อน */
        padding: 5px 10px;
        border-radius: 5px;
        }

        /* CSS สำหรับไฮไลต์พื้นหลังสีเขียว */
        .highlight-green {
        background-color: #c3e6cb;
        padding: 5px;
        border-radius: 5px;
        }

        .button-group {
            display: flex;
            justify-content: center;
            gap: 10px;
            margin-top: 20px;
        }

        .back-button, .back-button-secondary {
            padding: 10px 20px;
            font-size: 16px;
            cursor: pointer;
            text-align: center;
            text-decoration: none;
            outline: none;
            color: #fff;
            border: none;
            border-radius: 10px;
            box-shadow: 0 5px #999;
        }

        .back-button {
            background-color: #f44336;
        }

        .back-button:hover {
            background-color: #d32f2f;
        }

        .back-button-secondary {
            background-color: #008CBA;
        }

        .back-button-secondary:hover {
            background-color: #007B9A;
        }

        footer {
            text-align: center;
            color: #00000035;
            font-size: 14px;
            padding: 10px;
            width: 100%;
        }

         hr {
            border: none;
            border-top: 2px solid #ccc; /* ความหนาและสีของเส้น */
            margin: 20px 0; /* ระยะห่างบน-ล่างของเส้น */
            width: 100%; /* เส้นขยายเต็มหน้าจอ */
        }

        .content {
            margin-top: 20px; /* ระยะห่างจากเส้น */
            line-height: 1.6;
        }

        /* Mobile-Specific Adjustments */
        @media (max-width: 600px) {
            body {
                padding: 10px;
            }

            h1 {
                font-size: 20px; /* Reduce font size for mobile */
                padding: 5px; /* Reduce padding */
            }

            hr {
                width: 90%; /* ลดความกว้างของเส้นสำหรับหน้าจอเล็ก */
            }

            .content {
                font-size: 14px; /* ลดขนาดตัวอักษรสำหรับหน้าจอเล็ก */
            }
                
            .highlight-green {
                background-color: #c3e6cb; /* สีเขียวอ่อนสำหรับ highlight */
            }

            .highlight-dose {
                font-size: 20px; /* Adjust font size */
            }

            .section-title {
                font-size: 14px;
            }

            .table-wrapper {
                overflow-x: auto; /* Allow horizontal scrolling */
                margin-bottom: 15px;
            }

            table {
                font-size: 14px; /* Reduce font size */
            }

            th, td {
                padding: 8px; /* Reduce padding for smaller screens */
            }

        }
    </style>
</head>
<body>
        <h1>Meropenam Dosage Information</h1>

 <!-- แสดงค่าที่คำนวณได้จาก Flask -->
 <p><strong>PMA:</strong> {{ pma_weeks }} weeks and {{ pma_days }} days</p>
 <p><strong>Calc.:</strong> {{ calc }} weeks</p>
 <p><strong>Postnatal Age:</strong> {{ postnatal_days }} days</p>
 <p><strong>Birth Weight (BW):</strong> {{ "%.2f" | format(bw) }} kg</p>

 <!-- ส่วนแสดงผลลัพธ์การคำนวณ -->
 <div class="section-title">Calculated Dosage</div>
 <p>Recommended Dose:
   <span class="highlight-dose">
     {{ min_dose }} mg/kg/dose
   </span>
 </p>
 <p>Interval:
   <span class="highlight-dose">
     {{ interval }}
   </span>
 </p>

 <hr>

 <!-- ส่วนตารางหรือข้อมูลยาอื่น ๆ -->
 <div class="section-title">Dose</div>
 <div class="section-title">Intra-abdominal and non-CNS infections</div>

 <!-- ไฮไลต์ด้วย class="highlight-green" เมื่อ scenario ตรงกับเงื่อนไข -->
 <p {% if scenario == 'intra1' %}class="highlight-green"{% endif %}>
   <strong>• Less than 32 weeks GA and less than 14 days PNA :</strong>
   20 mg/kg IV every 12 hours
 </p>
 <p {% if scenario == 'intra2' %}class="highlight-green"{% endif %}>
   <strong>• Less than 32 weeks GA and 14 days PNA and older :</strong>
   20 mg/kg IV every 8 hours
 </p>
 <p {% if scenario == 'intra3' %}class="highlight-green"{% endif %}>
   <strong>• 32 weeks GA and older, and less than 14 days PNA :</strong>
   20 mg/kg IV every 8 hours
 </p>
 <p {% if scenario == 'intra4' %}class="highlight-green"{% endif %}>
   <strong>• 32 weeks GA and older, and 14 days PNA and older :</strong>
   30 mg/kg IV every 8 hours
 </p>

 <p>Consider concomitant use of an aminoglycoside antibiotic</p>
 <br>

 <!-- ส่วนอื่น ๆ (Meningitis, Anthrax) คงโค้ดเดิมไว้ตามต้องการ -->
 <div class="section-title">Meningitis, Bacterial</div>
 <p>Data regarding appropriate dosing for CNS infections are lacking. Consider 40 mg/kg/dose at the
 recommended age-specific dosing interval</p>
 <p><strong>• Less than 32 weeks GA and less than 14 days PNA :</strong> every 12 hours</p>
 <p><strong>• Less than 32 weeks GA and 14 days PNA and older :</strong> every 8 hours</p>
 <p><strong>• 32 weeks GA and older :</strong> every 8 hours</p>
 <br>

 <p><strong>
   Anthrax; meningitis or disseminated infection and <u>meningitis cannot be ruled out</u>
 </strong>
 (as part of a triple therapy regimen)
 </p>
 <p><strong>32 weeks gestational age to full-term</strong></p>
 <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>0 to 1 week :</strong> 20 mg/kg/dose IV every 8 hours</p>
 <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>1 to 4 weeks :</strong> 30 mg/kg/dose IV every 8 hours</p>
 <p><strong>Duration :</strong> 2 to 3 weeks or more until stable. Continue antimicrobial course of prophylaxis (usually oral therapy) for up to 60 days from onset of illness</p>
 <br>

 <p><strong>Anthrax; meningitis ruled out </strong>(as part of a combination regimen)</p>
 <p><strong>32 to 34 weeks gestational age </strong></p>
 <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>0 to 1 week :</strong> 13 mg/kg/dose IV every 8 hours</p>
 <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>1 to 4 weeks :</strong> 20 mg/kg/dose IV every 8 hours</p>
 <p><strong>34 weeks gestational age or older </strong></p>
 <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>0 to 4 weeks :</strong> 20 mg/kg/dose IV every 8 hours</p>
 <p><strong>Duration :</strong> 2 to 3 weeks or more until stable. Continue antimicrobial course of prophylaxis (usually oral therapy) for up to 60 days from onset of illness</p>
    <br>

    <p><strong>Anthrax; meningitis ruled out </strong>(as part of a combination regimen)</p>
    <p><strong>32 to 34 weeks gestational age </strong></p>
    <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>0 to 1 week :</strong> 13 mg/kg/dose IV every 8 hours</p>
    <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>1 to 4 weeks :</strong> 20 mg/kg/dose IV every 8 hours</p>
    <p><strong>34 weeks gestational age or older </strong></p>
    <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>0 to 4 weeks :</strong> 20 mg/kg/dose IV every 8 hours</p>
    <p><strong>Duration :</strong> 2 to 3 weeks or more until stable. Continue antimicrobial course of prophylaxis (usually
    oral therapy) for up to 60 days from onset of illness</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Administration</div>
        <p>Administer as an IV infusion over 30 minutes at a concentration of 1 to 20 mg/mL.
Recommended standard concentrations are 20 and 50 mg/mL</p>

<p><strong>Prolonged Infusion :</strong> There are some data that promote prolonged infusions (e.g. over 4
hours) particularly for resistant organisms in neonates. In contrast, infusions of 20 mg/kg
over 30 minutes were demonstrated pharmacokinetically to be adequate for very low birth weight infants. Stability of meropenem needs to be considered as it is dependent on diluent,
concentration, and temperature. Some studies demonstrated longer stability times</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Uses</div>
        <div class="section-title">Anthrax</div>
        <div class="section-title">Systemic Anthrax when meningitis can be ruled out (IV)</div>
        <div class="section-title">Combination IV Therapy</div>
        <p><strong>• Preferred :</strong> Ciprofloxacin. Alternatives in order of preference: meropenem, levofloxacin,
imipenem/cilastatin, or vancomycin. If strains are penicillin-susceptible, then penicillin G (preferred) or
ampicillin (alternative).</p>
        <p><strong>• Plus</strong></p>
        <p><strong>• Preferred :</strong> Clindamycin. Alternatives in order of preference: linezolid, doxycycline (not for neonates 37
weeks gestation or younger), or rifampin.</p>

        <div class="section-title">Systemic Anthrax (meningitis or disseminated infection and meningitis cannot be
ruled out) (IV)</div>
        <p><strong>Triple IV Therapy</strong></p>
        <p><strong>• Preferred :</strong>Ciprofloxacin. Alternatives in order of preference: levofloxacin or moxifloxacin</p>
        <p><strong>• Plus</strong></p>
        <p><strong>• Preferred :</strong>Meropenem. Alternatives in order of preference: imipenem/cilastatin or doripenem. If
strains are penicillin-susceptible, then penicillin G (preferred) or ampicillin (alternative).</p>
        <p><strong>• Plus</strong></p>
        <p><strong>• Preferred :</strong>Linezolid. Alternatives in order of preference: clindamycin or rifampin or as a last resort,
chloramphenicol</p>

        <p><strong>Intra-abdominal infections, suspected or complicated</strong>, or other serious infections
caused by susceptible Gram-negative organisms resistant to other antibiotics. May be
useful in treating neonates with meningitis, however, data are lacking.</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Pediatric FDA Approved Indications </div>
        <p><strong>Complicated skin/skin structure infections</strong>due to Staphylococcus aureus (methicillin-susceptible
isolates only), Streptococcus pyogenes, S agalactiae, viridans group streptococci, Enterococcus
faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus
mirabilis, Bacteroides fragilis, and Peptostreptococcus species in pediatric patients 3 months and
older</p>

        <p><strong>Intra-abdominal infections</strong> including complicated appendicitis and peritonitis caused by
viridans group streptococci, E coli, Klebsiella pneumoniae, P aeruginosa, B fragilis, B thetaiotaomicron,
and Peptostreptococcus species in pediatric patients 3 months and older. Meropenem is
considered an appropriate single agent for pediatric patients with a complicated extra-biliary intra-abdominal infection</p>

        <p><strong>Bacterial meningitis</strong> caused by S pneumoniae (penicillin-susceptible isolates), Haemophilus
influenzae , and Neisseria meningitidis in pediatric patients 3 months and older </p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Contraindications/Precautions </div>
        <p><strong>Contraindications </strong></p>
        <p><strong>Contraindicated </strong>in patients with known hypersensitivity to carbapenems or previous
anaphylactic reactions to beta-lactams. Serious and occasionally fatal hypersensitivity (anaphylactic)
reactions have been reported in patients receiving therapy with beta-lactams; these reactions are
more likely to occur in those with a history of hypersensitivity to other beta-lactams or to multiple
allergens. Before initiating therapy, obtain a detailed history of previous hypersensitivity
reactions.</p>

        <p><strong>Precautions </strong></p>
        <p><strong>Concomitant use : </strong>Coadministration with valproic acid or divalproex sodium is generally not
recommended due to a reduction in valproic acid concentrations that may not respond to a dose
increase. In patients with well-controlled seizures on valproic acid or divalproex sodium, antibiotics
other than carbapenems are recommended, and if coadministration of meropenem is necessary,
supplemental anticonvulsant therapy is recommended</p>

        <p><strong>Dermatologic : </strong>Severe cutaneous adverse reactions, including Stevens-Johnson syndrome, toxic
epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, erythema multiforme,
and acute generalized exanthematous pustulosis have been reported; if signs and symptoms appear,
immediately withdraw therapy and consider an alternative.</p>

        <p><strong>Neurological : </strong>Seizures and other CNS adverse events have been reported with meropenem
therapy; these occurred mainly in patients with CNS disorders (eg, brain lesions or history of
seizures) or patients with bacterial meningitis and/or compromised renal function.</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Adverse Effects</div>  
        <p>Diarrhea (4%), nausea/vomiting (1%) and rash (2%). May cause inflammation at the injection site. The
use of carbapenem antibiotics can result in the development of cephalosporin resistance
in Enterobacter, Pseudomonas, Serratia, Proteus, Citrobacter, and Acinetobacter species. The risks of
pseudomembranous colitis and fungal infections are also increased.</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Monitoring</div>  
        <p>Periodic CBC (for thrombocytosis and eosinophilia) and hepatic transaminases. Assess IV site for
signs of inflammation.</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Pharmacology</div>  
        <p><strong>Mechanism of action :</strong> Meropenem is a broad-spectrum carbapenem antibiotic that penetrates
well into the CSF and most body tissues. It exhibits time-dependent killing of gram-negative and
gram-positive pathogens, and the goal of therapy is to keep free drug concentrations above the MIC for at least 40% of the dosing interval. It is relatively stable to inactivation by human renal
dehydropeptidase.</p>

        <p><strong>Protein binding :</strong> Plasma protein binding is minimal.</p>
        <p><strong>Clearance :</strong> Directly related to renal function, and 70% of a dose is recovered intact in the urine.
Measured renal clearance and the effect of probenecid demonstrate that both glomerular filtration
and tubular secretion are involved in renal elimination.</p>
        <p><strong>Metabolism :</strong> Hepatic function does not affect pharmacokinetics.
Pharmacokinetic parameters in patients less than 3 months of age following treatment with
combination antibacterial drug therapy:</p>

<table>
        <thead>
            <tr>
                <th colspan="6">Pharmacokinetic Parameters</th>
            </tr>
           
      <tr>
        <!-- คอลัมน์แรกเป็นหัวข้อ "Parameters" -->
        <th rowspan="2" style="width: 15%;">Parameters</th>
        <!-- คอลัมน์หัวข้อย่อย 4 คอลัมน์ -->
        <th colspan="4">GA &amp; PNA Groups</th>
        <!-- คอลัมน์สุดท้าย "Overall" -->
        <th rowspan="2" style="width: 10%;">Overall</th>
      </tr>
      <tr>
        <th style="width: 20%;">
          GA &lt; 32 wks &amp;<br>
          PNA &lt; 2 wks<br>
          (20 mg/kg every 12 hrs)
        </th>
        <th style="width: 20%;">
          GA &lt; 32 wks &amp;<br>
          PNA &ge; 2 wks<br>
          (20 mg/kg every 8 hrs)
        </th>
        <th style="width: 20%;">
          GA &ge; 32 wks &amp;<br>
          PNA &lt; 2 wks<br>
          (20 mg/kg every 8 hrs)
        </th>
        <th style="width: 20%;">
          GA &ge; 32 wks &amp;<br>
          PNA &ge; 2 wks<br>
          (20 mg/kg every 6 hrs)
        </th>
      </tr>
    </thead>

    <tbody>
      <tr>
        <td>CL (L/hr/kg)</td>
        <td>0.089</td>
        <td>0.122</td>
        <td>0.135</td>
        <td>0.202</td>
        <td>0.119</td>
      </tr>
            <tr>
        <td>V (L/kg)</td>
        <td>0.489</td>
        <td>0.467</td>
        <td>0.463</td>
        <td>0.451</td>
        <td>0.468</td>
      </tr>
      <tr>
        <td>AUC (mcg/hr/mL)</td>
        <td>448</td>
        <td>491</td>
        <td>445</td>
        <td>444</td>
        <td>467</td>
      </tr>
      <tr>
        <td>Cmax (mcg/mL)</td>
        <td>44.3</td>
        <td>46.5</td>
        <td>44.9</td>
        <td>61</td>
        <td>46.9</td>
      </tr>
      <tr>
        <td>Cmin (mcg/mL)</td>
        <td>5.36</td>
        <td>6.65</td>
        <td>4.84</td>
        <td>2.1</td>
        <td>5.65</td>
      </tr>
      <tr>
        <td>T<sub>1/2</sub> (hr)</td>
        <td>3.82</td>
        <td>2.68</td>
        <td>2.33</td>
        <td>1.58</td>
        <td>2.68</td>
      </tr>

        <tr>
            <td colspan="4" style="text-align: left;">Values were obtained from a population pharmacokinetic analysis of sparse data</td>
        </tr>
        <tr>
            <td colspan="4" style="text-align: left;">GA: gestational age; PNA: postnatal age</td>
        </tr>
        <tr>
            <td colspan="4" style="text-align: left;">Merrem IV product information, 2014; AUC is from 0 to 24</td>
        </tr>
            </tbody>
    </table>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Special Considerations/Preparation</div>  
          <p><strong>Availability :</strong> Powder for injection in 500-mg, and 1000-mg vials.</p>
          <p><strong>Dilution and Stability</strong></p>
          <p><strong>IV Bolus :</strong> 10 mL of compatible diluent (500-mg vial) or 20 mL (1000-mg vial) for IV bolus. When
reconstituted with sterile water for injection up to 50 mg/mL, stable for up to 3 hours at room
temperature or up to 13 hours when refrigerated (at or up to 5 degrees C)</p>
          <p><strong>IV Infusion :</strong> Concentrations from 1 to 20 mg/mL, in NS, are stable for 1 hour at or up to 25
degrees C or 15 hours at or up to 5 degrees C. Concentrations from 1 to 20 mg/mL, in D5W,
should be used immediately.
Some studies demonstrated longer stability times</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Solution Compatibility</div>
          <p>D5W, D10W, and NS.</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Terminal Injection Site Compatibility</div>
          <p>Aminophylline, atropine, caspofungin, cimetidine, dexamethasone, digoxin, dobutamine, dopamine,
enalaprilat, fluconazole, furosemide, gentamicin, heparin, insulin, linezolid, metoclopramide,
milrinone, morphine, norepinephrine, phenobarbital, potassium chloride, ranitidine, and
vancomycin.</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Terminal Injection Site Incompatibility</div>
          <p>Acyclovir, amphotericin B, calcium gluconate, metronidazole, sodium bicarbonate, and zidovudine.</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="button-group">
            <a href="javascript:history.back()" class="back-button-secondary">Back</a>
            <a href="{{ url_for('index') }}" class="back-button">Back to Home</a>
        </div>
    
        <footer>
            <p>Developed by Sukhontha Boonsookchan | update {{ update_date }}</p>
        </footer>

</body>
</html>